GLP-1s in Hip and Knee Arthroplasty

Starting soon · Phase 4 · Has a placebo group

Conditions studied: Arthritis, Obesity & Overweight, GLP - 1

In brief

The number of people living with hip and knee arthritis continues to grow. A large amount of these people are also overweight and diagnosed with obesity. Obesity leads to more stress on hip and knee joints, causing them to wear out sooner. This process is called arthritis. When arthritis gets worse, the joints often need to be replaced due to pain and poor mobility. Very heavy patients often have other health problems that can impair the ability to manage arthritis. Excess weight and health problems can change the way heavy patients recover after surgery, leading to a greater risk of complications. A new type of medicine might be able to improve how obese patients manage their hip and knee pain, as well as improve outcomes after surgery. This type of medicine is called a GLP-1. Investigators will study 2 groups, with one receiving the medicine while the other does not. The goal is to understand how these medications work in the time leading up to surgery and in the early postoperative recovery phase. If these medications help, it may improve the care of high risk obese patients.

Key facts

Study ID: NCT07755085
Run by: Nova Scotia Health Authority
People needed: 100
Starts: 2026-10-01
Expected to finish: 2028-12-01
Last updated by the study team: 2026-08-10

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients with a diagnosis of hip or knee arthritis and are a deemed candidate for THA or TKA by an orthopaedic surgeon
Diagnosis of BMI 35+ with an obesity-related health condition (Coronary vascular disease, previous stroke, type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, asthma) or BMI 40+
Patients must be between 18-90 years of age
Able to provide informed consent

You may not qualify if…

Cognitive impairment that precludes study participation and compliance
Patients unwilling to undergo smoking cessation prior to surgery
Patients currently taking biologic medications that suppress the immune system
Patients currently taking GLP-1 medications
Patients with a contraindication to GLP-1 medication

Where it is running

Nova Scotia Health — Dartmouth, Nova Scotia, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.